Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases.

By J. V. van Burik, R. Hare, H. Solomon, M. Corrado, D. Kontoyiannis. Clinical Infectious Diseases, 2006

604 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. (2008, neutral): “are active against zygomycosis [1, 2, 11].”
Epidemiology of Invasive Mycoses in North America (2010, background): “It is also well known for causing infections in infants and neonates (Table 9) (Fridkin et al. 2006; Kuhn et al. 2004; Levy et al. 1998; Lupetti et al. 2002; Pfaller et al. 2008d; Reiss et al. 2008; Saiman et al. 2000; Sarvikivi et al. 2005; Saxen et al. 1995; Trofa et al. 2008; Van Asbeck et al. 20”
ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients (2016, methodology): “The ECIL-3 recommendations for the treatment of mucormycosis were mostly based on retrospective studies, registry data and small prospective non-controlled studies.(3,68-77) Few new data are available for the treatment of mucormycosis since the ECIL 4 and, therefore, the current recommendations are ”
Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium (2019, background): “113,133,134,138,139 The wide range reflects the pattern of organs involved, with competing risks from underlying conditions.”